Beacon Angels members conducted the following new business at its meeting on Tuesday, February 13, 2024:

We entertained new funding proposals from the following:

• Ankored (Seth Lieberman, providing an automated tracking platform designed for small to mid-sized organizations to streamline their compliance, including document collection, clearances, training, certificates, approvals, and audit logs.
• Robotics88, delivering aerial drones along with a mapping service subscription to land managers who conduct prescribed burns. The drones provide pre-burn fire prediction in the planning stage and post-burn objective evaluation.

We heard updates from the Beacon portfolio company,

• NF2 Therapeutics, developing gene replacement therapy to prevent deafness, loss of mobility and devastating NF2 brain tumors and a targeted antibody-drug conjugate to treat NF2 meningiomas.

Swiggart reported on funding rounds, by Series number, as follows.

Completed

• 123 Xeno (Series A ext’n $1.0 MM new money, $1.5 MM debt conversion) (PR=$85K; $177K invested);

Pending

• 112B Theromics developing tumor-targeting therapies (30K invested);
• 122 GelMEDIX (PR=$223K; $190K collected);
• 126 Mybiometry (Smith) offering early warning of asthma attacks up to 20 days in advance using intelligent diagnostics and connected monitoring ($35K collected).

Members reported on companies in due diligence:

• RealNose (Jim Doscher)) offers AI-trained, bio-programmable olfactory sensors that map scent profiles, initially to help doctors detect prostate cancer in patients.
• RestauRent (DD by Smith, Doscher & Jack Wagner), a B2B SAAS platform to directly book private events at venues that have event space for 15-300+ guests.